AMENDMENT TO ASSET PURCHASE AGREEMENT
THIS AMENDMENT TO ASSET PURCHASE AGREEMENT (this "Amendment") is entered into as of
February 8, 1996, by and among Utah Medical Products, Inc., a Utah corporation ("Purchaser"), OB Tech
Liquidating Company, L.L.C., a Delaware limited liability company (the "Company") and the successor in interest
to O.B. Tech, Inc., a California Corporation ("O.B. Tech"), and James J. Bochnowski (the "Agent").
R E C I T A L S
A. Purchaser, O.B. Tech, and the individuals and other entities identified on the signature pages to the Agreement
(as defined below) entered into an Asset Purchase Agreement dated January 4, 1994 (the "Agreement").
Pursuant to Section 3.7 of the Agreement, among other things, the Agent was irrevocably appointed as the agent
and attorney-in-fact of the shareholders of O.B. Tech that executed the Agreement to act in the name of such
shareholders for purposes of executing any documents and taking any actions that the Agent, in his sole
discretion, may deem necessary or desirable in connection with Agreement or any of the transactions
B. The parties now wish to amend the Agreement pursuant to Section 14.7 thereof, as set forth in this
Amendment. All capitalized terms used in the Amendment and not otherwise defined herein shall have the
respective meanings assigned to them in the Agreement.
NOW, THEREFORE, the parties agree as follows:
1. The product described on Exhibit A hereto as approved by the FDA under submission number K954619 shall
be deemed to constitute "Cordguard I" in place of the product identified as "Cordguard I" in the Agreement.
2. The parties acknowledge and agree that Purchaser has satisfied all of its obligations under Section 2.1 of the
Agreement and Section 2.1 is of no further force or effect.
3. Section 2.2 of the Agreement is hereby amended and restated in its entirety to read as follows:
2.2 Exclusivity. Purchaser shall retain exclusive ownership rights in, and exclusive rights to exploit, U.S. Pa